Servicios Personalizados
Revista
Articulo
Indicadores
- Citado por SciELO
- Accesos
Links relacionados
- Similares en SciELO
Compartir
Acta Obstétrica e Ginecológica Portuguesa
versión impresa ISSN 1646-5830
Resumen
SILVA, Ana Filipa; CASTRO, Andreia Cunha; FIGUEIREDO, Carlos José y SANTOS, Emília dos. Postmenopausal hormone replacement therapy and risk of breast and gynecologic cancer. Acta Obstet Ginecol Port [online]. 2023, vol.17, n.2, pp.135-150. Epub 30-Jun-2023. ISSN 1646-5830.
Hormone Therapy (HT) is the most effective treatment for symptom control during menopause due to hypoestrogenism. Studies that linked HT to the risk of breast cancer led to a decrease in its prescription. This article seeks to review the risk of breast and gynecologic cancer associated with HT use. It is concluded that it’s a safe and effective option in symptomatic menopausal woman up to the age of 60, without contraindications, in the first 10 years post-menopause. The main concern prescribing it is the risk of breast cancer, which is only significant with a prolonged use over 5 years.
Palabras clave : Hormone replacement therapy; Postmenopausal; Genital neoplasms, female; Breast neoplasms; Endometrial neoplasms; Cervical uterine neoplasms; Ovarian neoplasms.